FIGURE 8 from Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts
Year: 2024
Type: other
Abstract: TAK-243 inhibits tumor growth in ACC xenograft models and synergizes with the BCL2 inhibitor Venetoclax. A, H295R xenografts were treated with TAK-243 (10 and 20 mg/kg) intraperitoneally twice weekly and mean tumor volume was evaluated. Error bars indicate SEM (n = 5); tumor volume for each mouse on day 29 was shown individually on the right. B, Xenograft tissues collected on day 29 (H&E staining, immunostaining for anti-multi-ubiquitin and anti-cleaved caspase-3 antibodies). Top panel: control, bottom panel: TAK-243 (20 mg/kg) group. Scale bar: 200 µm. C, Left: CU-ACC1 xenografts were treated with TAK-243 (10 mg/kg) intraperitoneally twice weekly, venetoclax (100 mg/kg) orally five times weekly, and a combination of TAK-243 and venetoclax, and mean tumor volume was evaluated. Error bars indicate SEM (n = 5); tumor volume of each mouse on day 29 was shown separately. Right: Tumor weight of each treatment group on day 29. Horizontal lines indicate mean values and error bars indicate SEM.
Authors: Yasuhiro Arakawa, Ukhyun Jo, Suresh Kumar, Nai-Yun Sun, Fathi Elloumi, Anish Thomas, Nitin Roper, Diana Grace Varghese, Naoko Takebe, Xiaohu Zhang, Michele Ceribelli, David O. Holland, Erin Beck, Zina Itkin, Crystal McKnight, Kelli M. Wilson, Jameson Travers, Carleen Klumpp-Thomas, Craig J. Thomas, Chuong D. Hoang, Jonathan M. Hernandez, Jaydira Del Rivero, Yves Pommier
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4392952312